Latest filing published 02 Oct 2026 for OptimizeRx Corp, €3,064.
Insider track record
Andrew J. D'Silva: trading record in brief
Andrew J. D'Silva discloses dealings in OptimizeRx Corp to SEC (Form 4). In total, 8 filings cover trades dated from 21 August 2025 to 1 October 2026.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
The latest filing, published on 2 October 2026, reports a share grant of €3,064 in OptimizeRx Corp. Typically, a trade is published a median of 4 days after it takes place. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Andrew J. D'Silva
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 414 shares@ US$8.39Common StockSEC:0001628280-26-064386:0
- 1,243 shares@ US$7.710.0065% mcap24.5% of flowCommon StockSEC:0001628280-26-058584:0
- 57,600 shares0Common StockSEC:0001628280-26-058672:0
- 703 shares@ US$13.5124.3% of flowCommon StockSEC:0001628280-25-058409:0
- 868 shares@ US$14.0331.2% of flowCommon StockSEC:0001628280-25-057199:0
- 414 shares@ US$18.9820.0% of flowCommon StockSEC:0001628280-25-050744:0
- 10,417 shares0Common StockSEC:0001628280-25-044426:0
7 of 7 declarations
